ObsEva Announces Third Quarter 2019 Financial Results


– Reports Update on Three Women’s Health Product Candidates –

Focusing on Phase 3 Programs for Linzagolix and the Phase 2
Program for OBE022

– Company to Host Conference Call/Webcast Today at 8 am ET/2pm CET –


GENEVA, Switzerland and BOSTON, MA (November 7, 2019) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the third quarter ended September 30, 2019 and announced top line results of the IMPLANT 4 trial.

"Despite the unexpected results for IMPLANT 4, we remain optimistic and committed to the development of our innovative pipeline with potentially best in class product candidates for serving unmet medical needs of millions of women.  In particular, we are looking forward to PRIMROSE 2 study top line results, which we expect to announce this quarter” said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva.

Pipeline Update

1.       Nolasiban

IMPLANT 4 study did not meet primary endpoint: The Company has decided to discontinue the current development of nolasiban for IVF and will be exploring potential repositioning of the product.

2.       Linzagolix

· Completed Patient Randomization for Two Pivotal Phase 3 trials For Women with Uterine Fibroids (PRIMROSE 1 and PRIMROSE 2):   The studies include approximately 1,000 women in total with heavy menstrual bleeding (HMB) associated with uterine fibroids. The efficacy and safety of two oral doses of linzagolix are being studied, including 100mg once daily without hormonal add-back therapy (ABT) and 200mg once daily with ABT.

· Positive Phase 2b (EDELWEISS 1) Results Presented at the American Society of Reproductive Medicine (ASRM) Annual Meeting : ObsEva presented positive 52-week results of linzagolix for treating endometriosis-associated pain. 
· Phase 3 trials EDELWEISS 2 (U.S.) and EDELWEISS 3 (U.S. and Europe) Currently Enrolling Patients :  Each trial will enroll approximately 450 women with endometriosis-associated pain, and will include two oral doses of linzagolix, 75mg once daily without low-dose ABT and 200mg once daily with ABT. 

3.       OBE022 To Delay Preterm Birth

· Data Monitoring Committee Recommended Continuation of Phase 2 Study in Europe (PROLONG): In July 2019, the independent data monitoring committee (IDMC) recommended continuing the ongoing PROLONG trial with no modifications based upon the first 30 patients enrolled in Part B.  Part B is the multicenter, randomized, double-blind, placebo-controlled portion of the trial that will enroll up to 120 patients with preterm labor at a gestational age of between 24 and 34 weeks.


Anticipated Near-Term Milestones

ObsEva expects to achieve the following clinical and regulatory milestones in 2019 - 2020:

Fourth quarter 2019

  • Linzagolix: Report six-month primary endpoint data from the PRIMROSE 2 Phase 3 trial (U.S. and Europe) to treat HMB due to uterine fibroids.
  • OBE022: Receive interim update in 60 patients dosed in Part B of the PROLONG Phase 2a trial in acute pre-term labor and decide next steps in development.

Second Quarter 2020

·Linzagolix:  Report six-month primary endpoint data from the Phase 3 PRIMROSE 1 trial (U.S.) of linzagolix for the treatment of HMB due to uterine fibroids.

Second Half 2020

  • Linzagolix:
    • Read-out 12 month data for PRIMROSE 1 and PRIMROSE 2
    • Conduct pre-submission meeting with the European Medicines Agency and the U.S. Food and Drug Administration for uterine fibroid indication.
  • OBEO22: Report PROLONG study final results

Third Quarter 2019 Financial Results

Net loss for the third quarter of 2019 was $27.6 million, or $0.63 per share, compared with a net loss of $18.6 million, or $0.42 per share, for the third quarter of 2018.  Research and development expenses were $21.9 million and general and administrative expenses were $4.9 million for the third quarter of 2019, compared with $15.9 million and $3.1 million, respectively, for the third quarter of 2018.  The net loss for the third quarter of 2019 included non-cash expenses of $3.0 million for stock-based compensation, compared with $2.0 million in the prior-year period.

As of September 30, 2019, the Company had cash and cash equivalents of $91.0 million, compared with $138.6 million as of December 31, 2018.

The full Q3 2019 financial report shall be available from November 11, 2019, in the financial reports section of the Company’s website.

To access the financial reports section of the Company’s website, please click [here].
To access the Q3 2019 financial report directly, please click [here].

Conference Call Today

ObsEva will host a conference call and audio webcast today beginning at 8:00 a.m. Eastern Time/2:00 p.m. Central European Time to provide a business update and discuss the third quarter results.  Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers and referring to conference ID 9273485.  A live or archived webcast of the conference call can be accessed under the “Investors” section of ObsEva’s website

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan", "potential", "will", and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s product candidates, the timing of enrollment in and data from clinical trials and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2018, the Risk Factors filed as Exhibit 99.1 to ObsEva’s Form 6-K filed on August 7, 2019, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
+41 22 308 6220 Office
+41 79 476 26 87 Mobile

Media Contact U.S.:
Marion Janic
RooneyPartners LLC
+1 212 223 4017 Office
+1 646 537 5649 Mobile

CEO Office Contact:
Shauna Dillon
+41 22 552 1550

Investor Contact:
Mario Corso
Senior Director, Investor Relations
+1 857 972 9347 Office
+1 781 366 5726 Mobile

Consolidated Statements of Comprehensive Loss

     Three-month period
ended September 30,
    Nine-Month Period
Ended September 30,
(in USD ’000, except share and per share data) - unaudited   2019     2018     2019     2018  
Operating income other than revenue     5       2       11       10  
OPERATING EXPENSES                                
Research and development expenses     (21,935 )     (15,909 )     (70,513 )     (46,945 )
General and administrative expenses     (4,865 )     (3,137 )     (16,306 )     (10,287 )
Total operating expenses     (26,800 )     (19,045 )     (86,819 )     (57,231 )
OPERATING LOSS     (26,795 )     (19,043 )     (86,808 )     (57,221 )
Finance income     219       430       425       616  
Finance expense     (1,021 )           (1,608 )      
NET LOSS BEFORE TAX     (27,597 )     (18,613 )     (87,991 )     (56,605 )
Income tax (expense)     (10 )     23       (51 )     23  
NET LOSS FOR THE PERIOD     (27,607 )     (18,590 )     (88,042 )     (56,582 )
Net loss per share                                
Basic     (0.63 )     (0.42 )     (2.01 )     (1.45 )
Diluted     (0.63 )     (0.42 )     (2.01 )     (1.45 )
Weighted Average Number of Shares Outstanding     43,739,938       43,196,686       43,693,245       39,092,256  

Consolidated Balance Sheets

(in USD ’000) - unaudited   September 30,
    December 31,
Current assets                
Cash and cash equivalents     91,017       138,640  
Other receivables     776       885  
Prepaid expenses     5,964       5,715  
Total current assets     97,757       145,240  
Non-current assets                
Right-of-use assets     2,202        
Furniture, fixtures and equipment     261       319  
Intangible assets     26,608       21,608  
Other long-term assets     270       273  
Total non-current assets     29,341       22,200  
Total assets     127,098       167,440  
Current liabilities                
Current tax liability     46        
Other payables and current liabilities     6,515       2,766  
Accrued expenses     19,595       14,163  
Current lease liabilities     598        
Total current liabilities     26,754       16,929  
Non-current liabilities                
Non-current lease liabilities     1,665        
Non-current borrowings     24,830        
Post-employment obligations     3,608       3,547  
Other long-term liabilities     414       48  
Total non-current liabilities     30,517       3,595  
Shareholders’ equity                
Share capital     3,448       3,420  
Share premium     318,226       314,565  
Reserves     20,122       12,858  
Accumulated losses     (271,969 )     (183,927 )
Total shareholders’ equity     69,827       146,916  
Total liabilities and shareholders’ equity     127,098       167,440  



About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

The MILLA Group Selects the Leddar Pixell From LeddarTech for the MILLA POD Autonomous Shuttle25.11.2020 06:11:00 CETPress release

QUEBEC CITY, Nov. 25, 2020 (GLOBE NEWSWIRE) -- LeddarTech®, a global leader in Level 1-5 ADAS and AD sensing technology, is proud to have been selected by the MILLA Group as the supplier for their cocoon LiDAR sensor. The MILLA Group has selected the award-winning Leddar™ Pixell as the front-end LiDAR for their MILLA POD autonomous shuttle. The Leddar Pixell is the most robust solid-state LiDAR on the market. This sensor provides a 180-degree horizontal field of view (FoV) and can offer 360-degree coverage of a vehicle when four modules are used. The Leddar Pixell offers best-in-class shock and vibration resistance meeting ISO 16750-3 requirements and complies with the SAE J1455 standard for heavy dust intrusion, positioning the Leddar Pixell for use in the industrial vehicle markets requiring robustness and durability. Also, the Leddar Pixell is IP67 certified and provides an MTBF of more than 148,000 hours, which is equivalent to ten times that of scanning solutions. The Leddar Pixel

Golar LNG Partners LP: Q3 2020 results presentation24.11.2020 16:11:33 CETPress release

Golar LNG Partners LP 3rd Quarter 2020 results will be released before the NASDAQ opens on Monday, November 30, 2020. In connection with this a webcast presentation will be held at 4:30 P.M (London Time) on Monday, November 30, 2020. The presentation will be available to download from the Investor Relations section at Due to ongoing high levels of demand for their services, our platform providers highly recommended that participants join the conference call via the listen-only live webcast link provided. Sell-side analysts interested in raising a question during the Q&A session that will immediately follow the presentation should access the event via the conference call dial-in information below. Call handling may take longer than usual. You should therefore dial in 10-15 minutes prior to the start time. Information on how to ask questions will be given at the beginning of the Q&A session. There will be a limit of two questions per participant. a. Listen-only l

FORSVARET OG DFDS INDGÅR NY AFTALE24.11.2020 15:30:13 CETpressemeddelelse

Investor news DFDS og Joint Movement and Transportation Organisation (JMTO), som leverer strategisk transport i forbindelse med danske militære opgaver, har i dag indgået en ny aftale.I alt syv fragtfærger (ro-ro) stilles ifølge aftalen til rådighed for søtransport af militært materiel og udstyr i forbindelse med NATO-beredskabet, deltagelse i militære øvelser og operationer samt humanitære kriser. Aftalen, der er indgået efter et offentligt udbud af opgaven, erstatter en tidligere aftale mellem forsvaret og DFDS, og løber i seks år. I det daglige vil færgerne være indsat på DFDS’ ruter og blive stillet til rådighed for militæret, når og i det omfang forsvaret anmoder om det. Aftalen er desuden knyttet til ARK-projektet, et dansk-tysk samarbejde, der sikrer dansk og tysk forsvar adgang til og rådighed over kapacitet til søtransport i henhold til nationernes egne forpligtelser over for NATO. Kontakt Torben Carlsen, CEO +45 33 42 3201 Karina Deacon, CFO +45 33 42 3342 Søren Brøndholt Nie


Investor news Today, DFDS and the Joint Movement and Transport Organisation (JMTO), which provides strategic transport for Danish military missions, have entered into a new agreement. According to the agreement, a total of seven freight ferries (ro-ro) will be made available for the maritime transport of military materiel and equipment in connection with NATO preparedness, participation in military exercises and operations, and humanitarian crises. The agreement, concluded after the task went out to public tender, replaces an earlier agreement between the Danish Defence and DFDS, and runs for six years. On a day-to-day basis, the ferries will be deployed on DFDS’ routes, and will be made available to the military when and to the extent requested by the Danish Defence. The agreement is also linked to the ARK project, a Danish-German cooperation project, which ensures access to and availability of maritime transport capacity for Danish and German defences in accordance with the nations’

Cypress Development Reports Further Positive Metallurgical Results from Clayton Valley Lithium Project in Nevada24.11.2020 14:00:00 CETPress release

VANCOUVER, British Columbia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Cypress Development Corp. (TSX-V:CYP) (OTCQB:CYDVF) (Frankfurt:C1Z1) (“Cypress” or “the Company”) reports the completion of additional metallurgical testing following the positive Prefeasibility Study (PFS) published on the Company’s 100%-owned Clayton Valley Lithium Project in Nevada, USA. The testing was conducted at Continental Metallurgical Services in Montana and NORAM Engineering in British Columbia, in preparation for the Company’s pilot plant program as outlined in the PFS. Highlights Testing resulted in 80.2% extraction of lithium when a sodium chloride solution was used instead of distilled water in leaching claystone under Cypress’ sulfuric acid leach process. Lithium in the resulting leach solution was successfully concentrated at levels comparable to the PFS with limited interference by chlorides and other minerals present. The ability to tolerate high chloride levels in the process is significant because it al

RevoluGROUP Canada Inc. RevoluSEND Extends Remittance Reach with Thunes24.11.2020 14:00:00 CETPress release

VANCOUVER, British Columbia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt:IJA2) (the "Company") is pleased to announce that RevoluPAY EP S.L. has signed a Definitive Agreement ("DA") with Thunes on November 23rd, 2020. The DA, approved between RevoluPAY CEO Alfredo Manresa and Adrien Antoni, Director of Thunes, permits, with immediate effect, RevoluPAY® family remittances at over 9,000 collection partner agencies offered by in +100 countries. The parties have agreed upon delivery commissions payable to Thunes, independent of the amount sent and per individual beneficiary delivery and origination via RevoluPAY. The Scope of The Thunes Accord Today's agreement with Thunes expands the reach of the Company's remittance vertical RevoluSEND into supplementary countries, adding 38 nations previously unavailable, most notably crucial high volume remittance markets (Denoted Bold). The addition of Brazil, Chile, and Haiti in South America. As